Clinical Trial Detail

NCT ID NCT03067571
Title Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Daratumumab

Age Groups: adult senior

No variant requirements are available.